AADI News and Press, Aadi Bioscience Inc. From 03/03/23

Aadi Bioscience Announces Leadership Transition PR Newswire LOS ANGELES , March 3, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on precision therapies for genetically-defined cancers with alterati...

Aadi Bioscience to Present at the 43rd Annual Cowen Healthcare Conference PR Newswire LOS ANGELES , Feb. 22, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precisio...

Aadi Bioscience Presents PRECISION 1 Trial in Progress Poster and AMPECT Trial Final Analysis at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting PR Newswire Trial-in-progress poster showcases clinical trial design for PRECISION 1 and two additional ...

Aadi Bioscience, Inc. (AADI) Q3 2022 Earnings Conference Call November 9, 2022 08:30 ET Company Participants Marcy Graham - Senior Vice President of Investor Relations & Corporate Communications Neil Desai - President & Chief Executive Officer Brendan Del...

Aadi Bioscience press release ( NASDAQ: AADI ): Q3 GAAP EPS of -$0.68. Revenue of $4.24M. Cash, cash equivalents and short-term investments as of September 30, 2022 were $183.0 million as compared to $149.0 million as of December 31, 2021, which is expected to fund ope...

Aadi Bioscience Announces Financial Results for the Third Quarter of 2022 and Provides Corporate Update PR Newswire Completed $72.5 million PIPE financing extending cash runway into 2025 PRECISION 1 trial on-track with preliminary data expected in the first...

Aadi Bioscience ( NASDAQ: AADI ) said Tuesday it appointed Neil Desai, founder, president and CEO, as executive chairman. The company named its COO Brendan Delaney as president and CEO, effective Jan. 1. Prior to joining Aadi ( AADI ) in Sept. 2021, Delaney served ...

Aadi Bioscience Announces Planned Leadership Transition PR Newswire LOS ANGELES , Nov. 8, 2022 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on precision therapies for genetically-defined cancer...

The following slide deck was published by Aadi Bioscience, Inc. in conjunction with this event. For further details see: Aadi Bioscience (AADI) Investor Presentation - Slideshow

Aadi Bioscience to Present at Upcoming Investor Conferences PR Newswire LOS ANGELES , Nov. 3, 2022 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision thera...